Serum Institute Of INdia

Friday, Apr 19, 2024 | Last Update : 12:41 PM IST

Serum Institute of INdia

In August 2020, US-based vaccine maker Novavax, Inc had announced a licence agreement with SII for the development and commercialisation of NVX-CoV2373, its COVID-19 vaccine candidate, in low and middle-income countries and India. (Reuters Photo)

CDSCO seeks more data from SII, says Covovax not yet approved in country of origin

The DCGI office had granted SII permission to manufacture and stock Covovax on May 17

28 Nov 2021 12:47 PM

Any overzealous, though well-meaning judicial intervention may lead to unforeseen and unintended consequences in absence of any expert advice, the Centre told the top court. — AFP

Differential vaccine pricing is right, Centre tells Supreme Court

Government defends move, says it is to incentivise vaccine makers

11 May 2021 7:54 AM

A medical worker inoculates a policeman with a Covishield Covid-19 coronavirus vaccine at a vaccination camp, in Chennai. (AFP)

Covishield to cost Rs 400 a dose for states, Rs 600 for private hospitals

SII will serve 50% of the total production to the GoI vaccination program, and remaining will be for State governments and private hospitals

21 Apr 2021 1:55 PM

Union health secretary Rajesh Bhushan said this was done since a substantial proportion of the 45-plus population are in the organised sector of the economy and work in offices (private or government), or in manufacturing and services. (Representational Photo: AP)

Centre allows COVID-19 vaccination at places of work from April 11

This change in the government’s plan comes as the desired target for vaccinations is yet to be achieved

08 Apr 2021 8:53 AM

A staff member of the Rajawadi Hospital holds a vial of Covishield, AstraZeneca's Covid-19 coronavirus vaccine made by India's Serum Institute, in Mumbai. (AFP)

DCGI extends shelf life of Covishield from 6 to 9 months

In a letter to the Serum Institute, DCGI said it is permitted to apply the shelf life of nine months to unlabelled vials available on hand

31 Mar 2021 12:25 PM

The real motivation here is actually exfiltrating intellectual property and getting competitive advantage over Indian pharmaceutical companies. — PTI

Chinese hackers target Indian vaccine makers

Chinese hacking group APT10, also known as Stone Panda, identified gaps in the IT infra and supply chain software of Bharat Biotech and SII

02 Mar 2021 8:00 AM

Drugs Controller General of India Dr V G Somani along with Principal Director General of Press Information Bureau K S Dhatwalia (R) during a press conference to announce the approval of Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country, in New Delhi, Sunday, Jan. 03, 2021. (PTI)

Covishield to cost Rs.200 per dose, export banned by government

The government is now in a hurry to start vaccination drive, the schedule for which will be announced soon

05 Jan 2021 7:23 AM

Covishield has been recommended based on the human trial results in the the United Kingdom, the United States of America and India (Representational Image: AFP)

Covishield moves closer to approval

The recommendation on Covishield has been forwarded to the Drugs Controller General of India, which is likely to take a final call soon

02 Jan 2021 12:36 AM

A medic administers Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), during the Phase- 3 trials at the People's Medical College in Bhopal, Monday, Dec. 7, 2020. (PTI)

DCGI denies EUA to Covid vaccines shots of Bharat Biotech, Serum

‘Expert panels seeks more data on efficiency, safety’

09 Dec 2020 11:36 PM

The government is pinning its hopes for mass supply on Serum Institute, which lodged the first formal application for emergency-use approval of AstraZeneca’s shot on Monday. (AP)

Serum likely to supply COVID-19 vaccine at over Rs 250 per dose to Indian government

Poonawalla had said Serum will first focus on supplying the vaccine to Indians before distributing it to other countries

08 Dec 2020 11:43 AM

The DCGI order came after SII submitted the recommendations of the Data Safety Monitoring Board (DSMB), United Kingdom and DSMB India and sought permission to restart enrolment in the clinical trials. (AP)

SII to restart COVID vaccine trials as India tally breaches 50L mark

The trials of the Oxford COVID-19 vaccine candidate were halted world over after one volunteer developed 'unexplained illness'

17 Sep 2020 12:32 PM

Pausing trials for COVID-19 vaccine of AstraZeneca due to safety concerns is nothing new, scientists said while pointing out that ‘trials’ are experiments which may or may not work. (AFP)

Trials will have ups and downs, say scientists

Adverse effects were noted on two human subjects who volunteered for the phase 3 trials of AstraZeneca COVID-19 vaccine

11 Sep 2020 1:15 PM

Gurugram: Health workers collect swab samples for Covid-19 Rapid antigen testing at old Civil Hospital, Civil Lines, in Gurugram, Wednesday. (PTI)

COVID-19 in India: Serum Institute halts trials of AstraZeneca's vaccine

The move came a day after the company stated that it would push ahead with the trials in India

11 Sep 2020 3:21 AM

In this photo illustration, a syringe is displayed at the Hindustan Syringes factory in Faridabad. - India's biggest syringe manufacturer is ramping up its production to churn out a billion units, anticipating a surge in demand as the global race to find a COVID-19 coronavirus vaccine heats up.— AFP

Serum Institute of India: India will go ahead with Oxford COVID vaccine trials

The SII has been issued a show cause notice by Indian drug controller DCGI after one volunteer reported unwell in UK

10 Sep 2020 11:29 AM

Serum Institute of India said that trials of AstraZeneca Plc’s COVID-19 vaccine candidate in the country is ongoing and has not faced any issues. (Representative Image)

AstraZeneca's COVID-19 vaccine trials continue in India: Serum Institute

AstraZeneca said it has paused global trials, including large late-stage trials, due to an unexplained illness in a study participant

09 Sep 2020 4:20 PM

The Oxford vaccine candidate has been administered to two volunteers at the Bharathi Hospital in Pune.

Two volunteers who were given Oxford vaccine are fine

The vaccine trials are being conducted by the Serum Institute of India in Pune

27 Aug 2020 12:29 PM

The SII has selected 15 sites in India to conduct the phase-2 trial of the vaccine.

Phase-2 human trial of the Oxford COVID-19 vaccine candidate begins in India

The phase-2 trial will be conducted on 100 volunteers at some sites across the country.

27 Aug 2020 11:11 AM

Phase II human trial of Oxford vaccine begins in Pune. A scientist works over an experimental coronavirus vaccine in a laboratory. (AFP Photo)

Serum Institute begins phase 2 clinical trial of Oxford COVID vaccine

In all 25 candidates will given the vaccine in the next seven days, according to Dr Lalwani

26 Aug 2020 5:01 PM

DCGI gives nod to Serum Institute for phase 2, 3 trials of Oxford COVID-19 vaccine. (AP Photo)

Serum-Oxford COVID-19 vaccine gets DCGI grant for human trials in India

The panel had also recommended that the clinical trial sites which have been proposed for the study be distributed across India

03 Aug 2020 9:09 AM

Pune's Serum Institute of India's Covid vaccine to be out in the market by October, but only if human trials are successful . (Photo: Serum Institute of India)

Indian firm to test Covid vaccine in 3 weeks; if successful, drug won't be patented

If human clinical trials are successful, product will be out in the market by October

26 Apr 2020 1:55 PM

1 of 1

Columns

Mohan Guruswamy